About POET Technologies Inc. - Common Shares (POET)
POET Technologies Inc. is a company focused on advancing semiconductor technology by developing innovative solutions for optical and electronic devices. It specializes in combining photonics and electronics on a single chip, which enhances performance and reduces energy consumption for various applications, including telecommunications, data centers, and consumer electronics. The company's cutting-edge platforms aim to deliver high-speed connectivity and efficient processing capabilities, positioning it as a key player in the growing field of integrated photonics. Through its research and development initiatives, POET is committed to driving technological advancements that meet the increasing demands of the digital economy. Read More
LOS ANGELES, April 29, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against POET Technologies Inc. (“POET” or “the Company”) (NASDAQ: POET) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired POET Technologies Inc. (“POET” or the “Company”) (NASDAQ:POET) securities during the period of April 1, 2026 through April 27, 2026, inclusive (“the Class Period”).
Gibbs Mura announces that a securities class action lawsuit has been filed against POET Technologies on behalf of investors who acquired or purchased shares between April 1, 2026, and 08:57 AM ET on April 27, 2026.
Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired POET Technologies Inc. (NASDAQ: POET) securities between April 1, 2026 and 8:57 A.M. ET on April 27, 2026. POET Technologies describes itself as a "design and development company offering photonic integrated packaging solutions based on the POET Optical Interposer™, a novel platform that allows the seamless integration of electronic and photonic devices onto a single chip using advanced wafer-level semiconductor manufacturing techniques."
NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of POET Technologies Inc. (“POET” or the “Company”) (NASDAQ: POET) between April 1, 2026 and 08:57 AM ET on April 27, 2026, inclusive.
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against POET Technologies, Inc. (“POET Technologies” or the “Company”) (NASDAQ: POET) and reminds investors of the June 29, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
LOS ANGELES, April 28, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of POET Technologies Inc. (“POET” or “the Company”) (NASDAQ: POET) for violations of the securities laws.
Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of POET Technologies Inc. (NASDAQ: POET) between April 1, 2026 and 08:57 AM ET on April 27, 2026, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Poet Technologies investors under the federal securities laws.
While investors chase the GLP-1 drug boom, a critical bottleneck is emerging that could reshape the entire market— liver imaging simply doesn’t scale to meet the coming demand. As metabolic dysfunction–associated steatotic liver disease (MASLD) and GLP-1 therapies continue to expand globally, ENDRA Life Sciences (NASDAQ: NDRA) is positioning its TAEUS® (Thermo-Acoustic Enhanced UltraSound) platform to address a growing constraint in clinical trials and patient care: scalable liver imaging .
Shares of POET Technologies Inc. (“POET Technologies”) plummeted over 47% on April 27, 2026, after disclosing that Celestial AI, which was recently acquired by Marvell, had cancelled all of the company’s purchase orders, citing alleged confidentiality violations. Gibbs Mura is investigating a potential POET Technologies (NASDAQ: POET) Securities Class Action Lawsuit concerning whether POET Technologies has violated federal securities laws by providing false or misleading statements to investors.
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of POET Technologies Inc. (NASDAQ: POET) resulting from allegations that POET Technologies may have issued materially misleading business information to the investing public.
